Decreased functional response to Toll like receptor ligands in patients with oral cancer

Human Immunology

Volumn 74, Issue 8, 2013, Pages 927-936

  Paleja, B ^a   Anand, A ^a   Chaukar, D ^a   D'Cruz, A ^a   Chiplunkar, S ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALPHA BETA T LYMPHOCYTE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUTH CANCER; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

CPG ODN; CPG OLIGODEOXYNUCLEOTIDE TYPE A; IDO; INDOLE 2,3-DIOXYGENASE; LIPOPOLYSACCHARIDE; LPS; PAM3; PAM3CSK4; PGE2; PIC/POLY I:C; POLYINOSINIC:POLYCYTIDYLIC ACID; PROSTAGLANDIN E2;

CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTE ACTIVATION; MOUTH NEOPLASMS; NEOPLASM STAGING; POLY I-C; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS;

EID: 84879880798     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.018     Document Type: Article

References (39)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009, 45:309.
3. Nair U., Bartsch H., Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis 2004, 19:251.
4. Schaefer C., Kim G.G., Albers A., Hoermann K., Myers E.N., Whiteside T.L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005, 92:913.
5. Duray A., Demoulin S., Hubert P., Delvenne P., Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010, 2010:701657.
6. Whiteside T.L. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005, 24:95.
7. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606.
8. Kulkarni D.P., Wadia P.P., Pradhan T.N., Pathak A.K., Chiplunkar S.V. Mechanisms involved in the down-regulation of TCR zeta chain in tumor versus peripheral blood of oral cancer patients. Int J Cancer 2009, 124:1605.
9. Lopez-Albaitero A., Nayak J.V., Ogino T., Machandia A., Gooding W., DeLeo A.B., et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006, 176:3402.
10. Hoffmann T.K., Dworacki G., Tsukihiro T., Meidenbauer N., Gooding W., Johnson J.T., et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002, 8:2553.
11. Kaisho T., Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006, 117:979.
12. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987.
13. Oberg H.H., Juricke M., Kabelitz D., Wesch D. Regulation of T cell activation by TLR ligands. Eur J Cell Biol 2011, 90:582.
14. Desfrancois J., Moreau-Aubry A., Vignard V., Godet Y., Khammari A., Dreno B., et al. Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One 2010, 5:e8437.
15. Parel Y., Aurrand-Lions M., Scheja A., Dayer J.M., Roosnek E., Chizzolini C. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007, 56:3459.
16. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373.
17. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009, 1:949.
18. Goutagny N., Estornes Y., Hasan U., Lebecque S., Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012, 7:29.
19. Wesch D., Beetz S., Oberg H.H., Marget M., Krengel K., Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol 2006, 176:1348.
20. Deetz C.O., Hebbeler A.M., Propp N.A., Cairo C., Tikhonov I., Pauza C.D. Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect Immun 2006, 74:4505.
21. Pietschmann K., Beetz S., Welte S., Martens I., Gruen J., Oberg H.H., et al. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes. Scand J Immunol 2009, 70:245.
22. Dhodapkar M.V., Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 2011, 140:160.
23. Raftery M.J., Winau F., Giese T., Kaufmann S.H., Schaible U.E., Schonrich G. Viral danger signals control CD1d de novo synthesis and NKT cell activation. Eur J Immunol 2008, 38:668.
24. Tyznik A.J., Tupin E., Nagarajan N.A., Her M.J., Benedict C.A., Kronenberg M. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol 2008, 181:4452.
25. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637.
26. Rawlings D.J., Schwartz M.A., Jackson S.W., Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol 2012, 12:282.
27. Ortolani C., Forti E., Radin E., Cibin R., Cossarizza A. Cytofluorimetric identification of two populations of double positive (CD4+, CD8+) T lymphocytes in human peripheral blood. Biochem Biophys Res Commun 1993, 191:601.
28. Bagot M., Echchakir H., Mami-Chouaib F., Delfau-Larue M.H., Charue D., Bernheim A., et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998, 91:4331.
29. Mizuki M., Tagawa S., Machii T., Shibano M., Tatsumi E., Tsubaki K., et al. Phenotypical heterogeneity of CD4+CD8+ double-positive chronic T lymphoid leukemia. Leukemia 1998, 12:499.
30. Matsui M., Fukuyama H., Akiguchi I., Kameyama M. Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis. J Neurol 1989, 236:329.
31. Weiss L., Roux A., Garcia S., Demouchy C., Haeffner-Cavaillon N., Kazatchkine M.D., et al. Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. J Infect Dis 1998, 178:1158.
32. Desfrancois J., Derre L., Corvaisier M., Le Mevel B., Catros V., Jotereau F., et al. Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions. Int J Cancer 2009, 125:374.
33. Freeman L.M., Lam A., Petcu E., Smith R., Salajegheh A., Diamond P., et al. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model. J Immunol 2011, 187:3987.
34. Ferris R.L., Hunt J.L., Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 2005, 33:113.
35. Babu S., Blauvelt C.P., Kumaraswami V., Nutman T.B. Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection. J Immunol 2006, 176:3885.
36. Farina C., Theil D., Semlinger B., Hohlfeld R., Meinl E. Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. Int Immunol 2004, 16:799.
37. Millard A.L., Spirig R., Mueller N.J., Seebach J.D., Rieben R. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. Mol Immunol 2010, 47:2349.
38. Shen E., Lu L., Wu C. TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes. Scand J Immunol 2008, 67:560.
39. Lauzon N.M., Mian F., MacKenzie R., Ashkar A.A. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 2006, 241:102.